A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

Clinical trial NCT01614522 · COMPLETED

Trial details

NCT number: NCT01614522
Sponsor: ASLAN Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Stomach Neoplasms Cancer of Stomach Cancer of the Stomach Gastric Cancer Gastric Neoplasms

Start date: 2012-03-01
Primary completion: 2013-03-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.